MX2022007774A - Anticuerpos de union a abril modificados. - Google Patents
Anticuerpos de union a abril modificados.Info
- Publication number
- MX2022007774A MX2022007774A MX2022007774A MX2022007774A MX2022007774A MX 2022007774 A MX2022007774 A MX 2022007774A MX 2022007774 A MX2022007774 A MX 2022007774A MX 2022007774 A MX2022007774 A MX 2022007774A MX 2022007774 A MX2022007774 A MX 2022007774A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- antibodies
- binding antibodies
- april binding
- hapril
- Prior art date
Links
- 239000000203 mixture Substances 0.000 abstract 2
- 101000830600 Homo sapiens Tumor necrosis factor ligand superfamily member 13 Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Rehabilitation Therapy (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
Abstract
La divulgación se relaciona con anticuerpos de unión a APRIL, que se unen al mismo epítopo de APRIL humano que un anticuerpo que tiene un sitio de unión a antígeno de hAPRIL.01A. Los anticuerpos de la presente divulgación comprenden selecciones específicas de secuencias estructurales de los dominios VH y VL y tienen características inesperadas en comparación con hAPRIL.01A. La divulgación se relaciona además con composiciones que comprenden un anticuerpo de la invención y con los usos médicos y de diagnóstico de los anticuerpos y las composiciones.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL2014108A NL2014108B1 (en) | 2015-01-09 | 2015-01-09 | Altered april binding antibodies. |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022007774A true MX2022007774A (es) | 2022-08-10 |
Family
ID=53783809
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017009052A MX2017009052A (es) | 2015-01-09 | 2016-01-08 | Anticuerpos de unión a april modificados. |
MX2022007774A MX2022007774A (es) | 2015-01-09 | 2017-07-07 | Anticuerpos de union a abril modificados. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017009052A MX2017009052A (es) | 2015-01-09 | 2016-01-08 | Anticuerpos de unión a april modificados. |
Country Status (20)
Country | Link |
---|---|
US (4) | US9969808B2 (es) |
EP (2) | EP3242892B1 (es) |
JP (2) | JP6824190B2 (es) |
KR (2) | KR20230170120A (es) |
CN (1) | CN107207602B (es) |
AU (1) | AU2016205977B2 (es) |
BR (1) | BR112017014771A2 (es) |
CA (1) | CA2973286A1 (es) |
DK (1) | DK3242892T3 (es) |
EA (1) | EA201791270A1 (es) |
ES (1) | ES2902901T3 (es) |
HK (1) | HK1243435A1 (es) |
IL (1) | IL253306B (es) |
MA (1) | MA41313A (es) |
MX (2) | MX2017009052A (es) |
NL (1) | NL2014108B1 (es) |
PL (1) | PL3242892T3 (es) |
SG (1) | SG11201705589UA (es) |
WO (1) | WO2016110587A1 (es) |
ZA (2) | ZA201704920B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL2011406C2 (en) | 2013-09-06 | 2015-03-10 | Bionovion Holding B V | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides. |
NL2014108B1 (en) | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
PT3380522T (pt) | 2015-11-25 | 2024-02-14 | Visterra Inc | Moléculas de anticorpos contra april e suas utilizações |
PE20181535A1 (es) | 2015-12-16 | 2018-09-26 | Gritstone Oncology Inc | Identificacion, fabricacion y uso de neoantigeno |
WO2018236995A2 (en) * | 2017-06-20 | 2018-12-27 | Dana-Farber Cancer Institute, Inc. | METHODS FOR MODULATING REGULATORY T LYMPHOCYTES, REGULATORY B LYMPHOCYTES AND IMMUNE RESPONSES USING AVRIL-TACI INTERACTION MODULATORS |
JP7227237B2 (ja) | 2017-10-10 | 2023-02-21 | グリットストーン バイオ インコーポレイテッド | ホットスポットを利用した新生抗原の特定 |
AU2018373154A1 (en) | 2017-11-22 | 2020-07-02 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
US20200190163A1 (en) * | 2018-10-26 | 2020-06-18 | Lijun Wu | Humanized bcma-car-t cells |
WO2020144535A1 (en) | 2019-01-08 | 2020-07-16 | Aduro Biotech Holdings, Europe B.V. | Methods and compositions for treatment of multiple myeloma |
BR112022007128A2 (pt) * | 2019-10-15 | 2022-07-05 | Dragonfly Therapeutics Inc | Ligação de proteínas nkg2d, cd16 e flt3 |
TW202124449A (zh) * | 2019-10-15 | 2021-07-01 | 美商蜻蜓醫療公司 | 靶向flt3之抗體及其用途 |
CA3161516A1 (en) | 2019-12-17 | 2021-06-24 | Philip Thomas FROHLICH | Methods of treating iga nephropathy with atrasentan |
JP2023527563A (ja) * | 2020-05-29 | 2023-06-29 | チヌーク セラピューティクス,インコーポレイテッド | APRIL結合抗体によるIgA腎症を治療する方法 |
AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
EP4333869A1 (en) | 2021-05-07 | 2024-03-13 | Alpine Immune Sciences, Inc. | Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein |
US20240092921A1 (en) | 2022-04-25 | 2024-03-21 | Visterra, Inc. | Antibody molecules to april and uses thereof |
WO2024077018A2 (en) | 2022-10-04 | 2024-04-11 | Alpine Immune Sciences, Inc. | Methods and uses of taci-fc fusion immunomodulatory protein |
WO2024092240A1 (en) | 2022-10-28 | 2024-05-02 | Chinook Therapeutics, Inc. | Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US778A (en) | 1838-06-12 | Thomas wright | ||
US4946A (en) | 1847-01-26 | Improvement in carriage-wheels | ||
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD272023A3 (de) | 1985-12-04 | 1989-09-27 | Ilmenau Tech Hochschule | Vorrichtung, insbesondere zur praezisionslichtstrahlablenkung |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
KR100507431B1 (ko) | 1994-11-07 | 2005-12-21 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 종양괴사인자-γ |
US6171787B1 (en) | 1997-06-26 | 2001-01-09 | Abbott Laboratories | Member of the TNF family useful for treatment and diagnosis of disease |
EP1027431A2 (en) | 1997-09-12 | 2000-08-16 | Apotech R&D S.A. | April- a novel protein with growth effects |
DE60028830T2 (de) * | 2000-02-16 | 2007-01-18 | Genentech, Inc., South San Francisco | Anti-april antikörper und hybridomazellen |
AU2001282856A1 (en) | 2000-06-15 | 2001-12-24 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
CA2446734A1 (en) | 2001-05-24 | 2002-11-28 | Human Genome Sciences, Inc. | Antibodies against tumor necrosis factor delta (april) |
AU2003226356A1 (en) | 2002-04-12 | 2003-10-27 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
US7410483B2 (en) | 2003-05-23 | 2008-08-12 | Novare Surgical Systems, Inc. | Hand-actuated device for remote manipulation of a grasping tool |
DE602005022871D1 (de) | 2004-06-07 | 2010-09-23 | Univ Ramot | Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko |
UY30776A1 (es) * | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
CN102171247A (zh) | 2008-07-02 | 2011-08-31 | 特鲁比昂药品公司 | TNF-α拮抗剂多靶点结合蛋白 |
EP2321351B1 (en) * | 2008-08-18 | 2017-11-01 | Pfizer Inc. | Antibodies to ccr2 |
WO2010032061A1 (en) * | 2008-09-19 | 2010-03-25 | Medimmune Llc | Antibodies against sonic hedgehog homolog and uses thereof |
PL2403528T3 (pl) * | 2009-03-02 | 2017-08-31 | Aduro Biotech Holdings, Europe B.V. | Przeciwciała przeciwko ligandowi indukującemu proliferację (APRIL) |
CN101928345B (zh) * | 2010-06-21 | 2012-08-29 | 中国科学技术大学 | 一种人源化抗体及其人源化改造方法 |
NL2014108B1 (en) | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
PT3380522T (pt) * | 2015-11-25 | 2024-02-14 | Visterra Inc | Moléculas de anticorpos contra april e suas utilizações |
-
2015
- 2015-01-09 NL NL2014108A patent/NL2014108B1/en active
-
2016
- 2016-01-08 JP JP2017554648A patent/JP6824190B2/ja active Active
- 2016-01-08 US US14/991,708 patent/US9969808B2/en active Active
- 2016-01-08 SG SG11201705589UA patent/SG11201705589UA/en unknown
- 2016-01-08 CA CA2973286A patent/CA2973286A1/en active Pending
- 2016-01-08 KR KR1020237041391A patent/KR20230170120A/ko active Application Filing
- 2016-01-08 EP EP16700803.6A patent/EP3242892B1/en active Active
- 2016-01-08 DK DK16700803.6T patent/DK3242892T3/da active
- 2016-01-08 EA EA201791270A patent/EA201791270A1/ru unknown
- 2016-01-08 WO PCT/EP2016/050314 patent/WO2016110587A1/en active Application Filing
- 2016-01-08 AU AU2016205977A patent/AU2016205977B2/en active Active
- 2016-01-08 KR KR1020177020607A patent/KR102612373B1/ko active IP Right Grant
- 2016-01-08 MA MA041313A patent/MA41313A/fr unknown
- 2016-01-08 CN CN201680006375.6A patent/CN107207602B/zh active Active
- 2016-01-08 BR BR112017014771-8A patent/BR112017014771A2/pt active Search and Examination
- 2016-01-08 MX MX2017009052A patent/MX2017009052A/es unknown
- 2016-01-08 PL PL16700803T patent/PL3242892T3/pl unknown
- 2016-01-08 EP EP21203559.6A patent/EP4029879A1/en active Pending
- 2016-01-08 ES ES16700803T patent/ES2902901T3/es active Active
-
2017
- 2017-07-04 IL IL253306A patent/IL253306B/en active IP Right Grant
- 2017-07-07 MX MX2022007774A patent/MX2022007774A/es unknown
- 2017-07-19 ZA ZA2017/04920A patent/ZA201704920B/en unknown
-
2018
- 2018-02-28 HK HK18102920.1A patent/HK1243435A1/zh unknown
- 2018-05-14 US US15/978,699 patent/US10377830B2/en active Active
- 2018-06-27 ZA ZA2018/04317A patent/ZA201804317B/en unknown
-
2019
- 2019-08-12 US US16/538,526 patent/US10961316B2/en active Active
-
2021
- 2021-01-12 JP JP2021002780A patent/JP7060728B2/ja active Active
- 2021-03-29 US US17/301,201 patent/US20210221900A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022007774A (es) | Anticuerpos de union a abril modificados. | |
PH12018502478A1 (en) | Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen | |
MX2022015901A (es) | Proteinas de union biespecificas y usos de las mismas. | |
PH12017502358A1 (en) | Factor xi antibodies and methods of use | |
EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
EA201791485A1 (ru) | Анти-cd47-антитела и их применения | |
SA517381703B1 (ar) | C10orf54 - أجسام مضادة لـ واستخداماتها | |
PH12018501882A1 (en) | Binding proteins and methods of use thereof | |
PH12021550690A1 (en) | Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies | |
PH12014502527B1 (en) | St2 antigen binding proteins | |
MX2018008934A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso. | |
PH12016501644B1 (en) | Binding proteins and methods of use thereof | |
EP4223874A3 (en) | Human anti-il-33 neutralizing monoclonal antibody | |
WO2013188693A8 (en) | Antigen binding constructs to cd3 | |
WO2016014434A3 (en) | Anti-cd74 antibodies, compositions comprising anti-cd74 antibodies and methods of using anti-cd74 antibodies | |
MX2016009877A (es) | Anticuerpos anti-baff novedosos. | |
PH12021550521A1 (en) | Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof | |
MX2021006362A (es) | Anticuerpos de dominio simple contra cll-1. | |
CR20210094A (es) | ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ENVOLTURA DEL VIRUS ZIKA Y USOS DE LOS MISMOS (Divisional 2019-0193) | |
EA202092085A1 (ru) | ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ | |
MA40526A (fr) | Protéines de fixation antigénique fixant le cxcr3 | |
MX2021000280A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. | |
MX2021000287A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. | |
MX2016014726A (es) | Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1. | |
MX2021000288A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. |